Cardiovascular diseases (CVD) account for one of every three deaths in the United States and are ranked as the leading cause of mortality worldwide. While significant effort has been directed towards elucidating the mechanisms governing the initiation and progression of CVD, much remains unclear. High density lipoprotein (HDL) is regarded to be protective against CVD due to its many anti-atherogenic properties, such as removing excess cholesterol from cells, preventing inflammation, and preventing cell death. Current evidence suggests that the risk for CVD depends more on HDL particle functionality, rather than HDL- cholesterol (HDL-C) levels. Risk factors for CVD including obesity, hypercholesterolemia, and hypertension increase oxidative stress and the formation of lipid dicarbonyls. Oxidative stress generates isolevuglandins (isoLGs), a family of high reactive lipid dicarbonyls that react with lysine residues of proteins and headgroups of phosphatidylethanolamines (PEs). Importantly, isoLG adduct levels are elevated in atherosclerosis, and correlate with CVD risk more strongly than low-density lipoprotein (LDL) and cholesterol levels. Interestingly, these isoLG adducts are not associated with LDL to a significant degree, raising the possibility that isoLG preferentially modifies HDL and impairs its anti-atherogenic functions. Given the many important functions of HDL, determining the consequences of isoLG modification on HDL structure, composition, and function is imperative for developing novel therapeutics to protect against atherosclerosis. My research plan will utilize a combination of structural biology, mass spectrometry, in vitro and in vivo approaches, and small molecule scavengers to: i) determine the functional consequences of isoLG modification on HDL subpopulations; ii) define the specific localization of isoLG adducts on HDL structural proteins; iii) determine the specific component of HDL (protein versus lipid) that is responsible for inflammation; iv) test the efficacy of isoLG scavengers in reducing atherosclerosis in vivo; v) compare analogues of scavengers in their abilities to preserve HDL structure-function in vitro. The goal of all my aims is to develop an understanding of the contribution of lipid dicarbonyl modification of HDL in atherogenesis. My long-term research goals are to identify the contributions of oxidized lipids in altering lipoprotein function and metabolism (LDL, HDL, chylomicrons), and to develop effective strategies to target specific mechanisms that contribute to atherosclerosis initiation and progression. This fellowship will help me build a research program that will lead to a productive career as an independent investigator of oxidative modifications of lipoproteins in CVD.
Isolevuglandins (isoLGs) are lipid dicarbonyls that react extremely rapidly with proteins and phospholipids, and are significantly elevated in atherosclerosis. Interestingly, isoLG adducts are primarily associated to plasma proteins other than those found on low density lipoprotein (LDL), suggesting the possibility that isoLG modification of high density lipoprotein (HDL) is the major contributor to atherogenesis. This research project will determine the contribution of isoLG modification to alterations in HDL structure and function, and will yield findings important for the development of new therapies, such as dicarbonyl scavengers, in the prevention of atherosclerosis.
| May-Zhang, Linda S; Yermalitsky, Valery; Huang, Jiansheng et al. (2018) Modification by isolevuglandins, highly reactive ?-ketoaldehydes, deleteriously alters high-density lipoprotein structure and function. J Biol Chem 293:9176-9187 |
| Davies, Sean S; Zhang, Linda S (2017) Reactive Carbonyl Species Scavengers-Novel Therapeutic Approaches for Chronic Diseases. Curr Pharmacol Rep 3:51-67 |
